C. Elegans Genetic Strategies to Identify Novel Parkinson's Disease-associated Therapeutic Targets and Leads

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

This chapter presents C. elegans genetic strategies to identify novel Parkinson's disease (PD)-associated therapeutic targets and leads. C. elegans is a powerful tool for genetic analysis and determination of molecular mechanisms involved PD-associated DA neuron cell death. C. elegans is also a powerful and facile system for drug discovery and target validation. The worm is sensitive to a number of human neuroreactive compounds including acetylcholine receptor agonist, anesthetics, cholinesterase inhibitors, immunosupressants, and serotonin, GABA, and dopamine-related compounds, and these drugs appear to interact with the worm homologs and at the orthologous active sites. A C. elegans toxin-based therapeutic lead screen provides opportunities to select compounds that protect against different steps of the neurodegeneration process. The identification of the D2 agonist quinpirole (QPR), bromocriptine (BMC), and the mixed D1/D2 agonist dihydrexidine as neuroprotective compounds is analyzed. It is suggested that C. elegans will play an integral role in the identification in the future of novel human therapeutic targets and leads.

Original languageEnglish (US)
Title of host publicationParkinson's Disease
PublisherElsevier Inc.
Pages361-368
Number of pages8
ISBN (Print)9780123740281
DOIs
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'C. Elegans Genetic Strategies to Identify Novel Parkinson's Disease-associated Therapeutic Targets and Leads'. Together they form a unique fingerprint.

  • Cite this